Image For Activity Cover
The Lead Episode 36: One-Year Outcomes Following Stereotactic Body Radiotherapy for Refractory Ventricular Tachycardia
Description
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by guests Esseim Sharma, MD, of University Hospitals Cleveland, and Paul C Zei, MD, PhD, FHRS, of Brigham and Women's Hospital to discuss One-Year Outcomes Following Stereotactic Body Radiotherapy for Refractory Ventricular Tachycardia. Cardiac stereotactic body radiotherapy (SBRT) has emerged as a promising noninvasive treatment for refractory ventricular tachycardia (VT). The objective is to describe the safety and effectiveness of SBRT for VT in refractory to extensive ablation. For a select group of high-risk patients with VT refractory to standard therapy, SBRT is associated with a reduction of in VT and appropriate ICD therapies.
Learning Objectives
  • To learn about the experience of a single center on outcomes after SBRT for treatment of VT.
Article Authors and Podcast Contributors
Article Authors
Arkles J, Markman T, Trevillian R, Yegya-Raman N, Garg L, Nazarian S, Santangeli P, Garcia F, Callans D, Frankel DS, Supple G.

Podcast Contributors
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital
Esseim Sharma, MD, of University Hospitals Cleveland
Paul C Zei, MD, PhD, FHRS, of Brigham and Women's Hospital

Disclosure Policy

ACE Disclosure Policy

The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.

 

Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.


ACCME Definition:

*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Examples of such organizations include:

  • Advertising, marketing, or communication firms whose clients are ineligible companies
  • Bio-medical startups that have begun a governmental regulatory approval process
  • Compounding pharmacies that manufacture proprietary compounds
  • Device manufacturers or distributors
  • Diagnostic labs that sell proprietary products
  • Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
  • Manufacturers of health-related wearable products
  • Pharmaceutical companies or distributors
  • Pharmacy benefit managers
  • Reagent manufacturers or sellers

 

All relevant financial relationships have been mitigated.

Host Disclosure(s):
W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic

Contributor Disclosure(s):
E. Sharma: No relevant financial relationships with ineligible companies to disclose. 
P. Zei: Honoraria/Speaking/Consulting Fee: Varian Medical Systems, Biosense Webster, Inc., Abbott; Research (Contracted Grants for PIs Named Investigators Only): Biosense Webster, Inc.; Stocks (Publicly Traded): Affera, Inc.


Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose. 
S. Sailor: No relevant financial relationships with ineligible companies to disclose.
S. Colbert: No relevant financial relationships with ineligible companies to disclose.
Summary
Availability: On-Demand
Cost: FREE
Credit Offered:
No Credit Offered
Recommended
  Heart Rhythm Society
1325 G Street NW, Suite 500
Washington, DC 20005
P: 202-464-3400 F: 202-464-3401
E: questions@heartrhythm365.org
© Heart Rhythm Society
Privacy Policy | Cookie Declaration | Linking Policy | Patient Education Disclaimer | State Nonprofit Disclosures | FAQ
 
Android App Download IOS App Download Powered By